29 clinical studies, which evaluated both mental health and SUD outcomes in patients with co-occurring bipolar disorders and SUDs.
Our findings suggest the potential of valproate sodium and lamotrigine as preferred pharmacological agents for the treatment of co-occurring psychiatric and substance use outcomes in these patients. However, many of the reviewed studies are of open-label designs and of modest sample sizes.
Thus, given the gaps in our knowledge, recommendations for treatment of this common and important co-morbidity are preliminary. Accordingly, the conduct of larger, randomized controlled trials for this co-morbidity is clearly needed. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
100 Stokes St; Alcohol; Bipolar Disorder; Cannabis; Cocaine; Methamphetamine; Opioids; Pharmacology; Pharmacotherapy Treatment; Poly Substance Dependence; Stimulants; Substance Dependence; Substance Use Disorder; Tobacco
PMID: 31077521 DOI: 10.1111/bdi.12794 Share Supplemental Content —
View the Original article